Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Curis, Inc.
National Institutes of Health Clinical Center (CC)
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
Taiho Oncology, Inc.
CareDx
Center for International Blood and Marrow Transplant Research
Novartis
M.D. Anderson Cancer Center
Shattuck Labs, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Clinical Hub for Interventional Research (CHOIR)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
AstraZeneca
Takeda
National Cancer Institute (NCI)
Center for International Blood and Marrow Transplant Research
Novartis
Assistance Publique - Hôpitaux de Paris
Seagen Inc.
University of Washington
Incyte Corporation
Incyte Corporation
National Cancer Institute (NCI)
Crossbow Therapeutics, Inc.
Incyte Corporation
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
University of Virginia
Jonsson Comprehensive Cancer Center
University of Miami
Prelude Therapeutics
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
Fred Hutchinson Cancer Center
Assistance Publique - Hôpitaux de Paris